The history of Sildenafil presents a challenging picture for shareholders. While the initial release generated significant returns, the end of its exclusive rights opened the door to generic competitors, dramatically diminishing revenue. This presents a unique here challenge for drug manufacturers banking on similar blockbuster offerings, suggestin

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, generating billions in sales , its exclusivity period created a wave of lower-priced alternatives , significantly diminishing its dominance. While some firms may try to capitalize on similar conditions , the current landscape d